IP Verse

Dr Reddys Laboratories competitive analysis

Latest publications and patents of Dr Reddys Laboratories New

Explore the latest publications and patents granted to Dr Reddys Laboratories, showcasing their recent innovations and technological advancements.

Last updated on: Sep 28, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Dr Reddys Laboratories

EP3414256
Jan 19, 2022Amine Salt Of Obeticholic AcidGranted And Under Opposition
EP2809773
Sep 2, 2020Process Of Modulating Man5 And/Or Afucosylation Content Of Glycoprotein CompositionRevoked
EP2018025217
Feb 8, 2018A System And Method Of Monitoring And Controlling The Usage Behaviour Of An Electronic Cigarette -
EP2760864
Jan 24, 20185 - Benzylaminomethyl - 6 - Aminopyrazolo [3, 4 -B]Pyridine Derivatives As Cholesteryl Ester -Transfer Protein (Cetp) Inhibitors Useful For The Treatment Of AtherosclerosisNo Opposition Filed Within Time Limit

Latest oppositions filed by Dr Reddys Laboratories

Explore patent oppositions filed by Dr Reddys Laboratories against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Oct 2, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP3689365
Use Of Long-Acting Glp-1 PeptidesNOVO NORDISKAug 27, 2025
EP2959894
S1P Receptor Modulators For Treating Multiple SclerosisNOVARTISJul 12, 2023
EP2478907
Methods And Compositions For Treating CancerCOUGAR BIOTECHNOLOGYJan 14, 2022
EP2493466
Novel Antitumoral Use Of CabazitaxelAVENTIS PHARMAMar 31, 2021
EP3294285
Cabazitaxel And Its Use For Treating CancerAVENTIS PHARMAAug 26, 2020
EP2766040
Uses For And Article Of Manufacture Including Her2 Dimerization Inhibitor PertuzumabF HOFFMANN LA ROCHEFeb 17, 2020
EP2825558
Combination Therapy For The Treatment Of Ovarian CancerF HOFFMANN LA ROCHEFeb 17, 2020
EP3351246
Rapamycin Derivative For The Treatment Of A Solid Tumor Associated With Deregulated AngiogenesisNOVARTISJan 29, 2020
EP3111954
Methods Of Treating Ankylosing Spondylitis Or Psoriatic Arthritis Using Anti-Il-17 AntibodiesNOVARTISJan 2, 2020
EP3300721
Propylene Glycol-Containing Peptide Formulations Which Are Optimal For Production And For Use In Injection DevicesNOVO NORDISKDec 5, 2019

Latest patents of Dr Reddys Laboratories opposed by its competitors

Explore Dr Reddys Laboratories's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 2, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3414256
Jan 19, 2022Amine Salt Of Obeticholic Acid1
EP2809773
Sep 2, 2020Process Of Modulating Man5 And/Or Afucosylation Content Of Glycoprotein Composition5

Latest PTAB cases involving Dr Reddys Laboratories

Discover the latest PTAB cases involving Dr Reddys Laboratories, highlighting their recent legal challenges and patent disputes.

Last updated on: Oct 4, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Dr Reddys Laboratories

IPR2024-00563Feb 21, 2024DR REDDYS LABORATORIESEYE THERAPIESTerminated-Settled
IPR2024-00467Jan 24, 2024DR REDDYS LABORATORIESEYE THERAPIESTerminated-Settled
IPR2024-00009Oct 20, 2023DR REDDYS LABORATORIESNOVO NORDISKTerminated-Settled
IPR2023-00052Oct 14, 2022DR REDDYS LABORATORIESGENENTECHFinal Written Decision
PGR2022-00023Feb 3, 2022DR REDDYS LABORATORIESGENENTECHFinal Written Decision
IPR2020-01060Jun 11, 2020DR REDDYS LABORATORIESMERCK SHARP & DOHMEFinal Written Decision
IPR2019-00329Nov 13, 2018DR REDDYS LABORATORIESINDIVIOR UKFinal Written Decision
IPR2019-00328Nov 13, 2018DR REDDYS LABORATORIESINDIVIOR UKInstitution Denied
IPR2018-01507Aug 3, 2018DR REDDYS LABORATORIESCELGENEInstitution Denied
IPR2018-01509Aug 3, 2018DR REDDYS LABORATORIESCELGENEInstitution Denied

Peer Comparison New

IP litigation analysis comparing Dr Reddys Laboratories with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 2, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases FacedStrategy Type
DR REDDYS LABORATORIES9627 - Highly Aggressive
CELGENE - 65 - 11Non-Active
GALDERMA LABORATORIES - - - 3Non-Active
HELSINN HEALTHCARE - - - 12Non-Active